Money Runners

[ADVFN_bioking]

EVOK (MC $21M) HOT FDA Play /Drug targeting $3+ BILLION Market

MEGA Drug targeting a $3+ BILLION Market is close to NDA-Resubmission expected before year end with potential FDA approval in Q2 .Market cap of $21 million is a PURE GIFT , this low float stock could run to $4+ even BEFORE FDA Decision . Now is the perfect time to load up before the news about NDA resubmission hit the wire which likely will attract more new investors .GL


Evoke Pharma (EVOK)

Market-Cap: $24 Million
Cash: $6.5 Million
Price: $1

Shares Out: 24.1 Million


Presentation
https://evokepharmainc.gcs-web.com/static-files/0f21016a-d472-4005-a293-dd8d02a857e7


•Gimoti™: Novel nasal delivery of metoclopramide for the symptomatic relief of acute and recurrent diabetic gastroparesis in women

•Large market opportunity:~12-16M patients with symptoms (80% women); ~2-3M currently treated in US given limited efficacy from few available treatment options

•Only one FDA-approved therapy for gastroparesis: Metoclopramide (oral & IV) still has ~4M prescriptions of the oral medication prescribed annually

•Positive data from pivotal comparative exposure PK study: Gimoti demonstrated AUC equivalence

•Estimated $3-4B prescription market

•Resubmission of 505(b)(2) NDA expected Q4 2019

If approved, Gimoti would be the first non-oral pharmacotherapy for gastroparesis approved in 40 years; metoclopramide is currently available in oral and injectable formulations.